Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCMSCs for Moderate to Severe Psoriasis
NCT03745417Phase 2Unknown
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in psoriasis, sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Psoriasis Area and Severity Index improvement rate at 12 weeks. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03745417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745417.